Palbociclib is one of the most successful drugs used in the treatment of various types of breast cancer, such as estrogen-receptor positive (HR+), HER2-negative advanced, or metastatic breast cancer. It contains palbociclib as an active ingredient and is coupled with other hormonal therapies such as Letrozole and Fulvestrant. It works by blocking two important proteins of cancer cells called CDK4 and CDK6. These proteins are essential for cancer growth. Therefore, by blocking them, palbociclib slows down or stops the spread of the tumor.
The most frequent side effects include nausea, fatigue, diarrhea, vomiting, hair thinning, stomatitis, and loss of appetite. Other particular hematological toxicities include reducing red blood cells and platelets, anemia, and infection. Symptoms like fever, chills, bleeding, bruising, etc., need immediate medical attention.